NCT06687616 is a NA clinical trial of SynerGI in IBS - Irritable Bowel Syndrome, sponsored by Christopher Almario.

Who is sponsoring NCT06687616?

NCT06687616 is sponsored by Christopher Almario.

What drugs are being tested in NCT06687616?

Interventions in NCT06687616: SynerGI, Sham VR.

What condition does NCT06687616 study?

NCT06687616 studies IBS - Irritable Bowel Syndrome.

Is NCT06687616 still recruiting?

NCT06687616 is currently completed. Last updated 8 December 2025.

Last reviewed 2025-12-08 · How we verify

NCT06687616

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RCT of VR Therapy for IBS

Completed NA Last updated 8 December 2025

What this trial tests

NA trial testing SynerGI in IBS - Irritable Bowel Syndrome in 73 participants. Completed in 25 November 2025.

Timeline

26 February 2025

Primary endpoint
21 November 2025

25 November 2025

Quick facts

Lead sponsor	Christopher Almario
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	73
Start date	26 February 2025
Primary completion	21 November 2025
Estimated completion	25 November 2025
Sites	2 locations across United States

Drugs / interventions tested

SynerGI
Sham VR

Conditions studied

IBS - Irritable Bowel Syndrome — all drugs for IBS - Irritable Bowel Syndrome →

Sponsor

Christopher Almario

Who can join

10 and older, any sex, with IBS - Irritable Bowel Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Through a pilot randomized controlled trial (RCT), the aim is to test the clinical impact and feasibility of a virtual reality (VR) cognitive behavioral therapy (CBT) program versus sham VR among patients with irritable bowel syndrome (IBS). It is hypothesized that using VR-administered CBT may reduce abdominal pain, leading to improved overall physical, psychological, and social functioning when compared to sham VR.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for IBS - Irritable Bowel Syndrome

Currently open trials in the same condition.

NCT06993272 — Relaxation Music for Chronic Pain · NA · active not recruiting
NCT06684470 — Novel Pilot Study to Treat Symptoms of IBS With Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodul · EARLY_PHASE1 · recruiting
NCT06117865 — Digital Treatment of Irritable Bowel Syndrome (IBS) · NA · active not recruiting
NCT06215222 — Capsule Microbiota Sampling in IBS/Functional Gastrointestinal Disease · recruiting
NCT05815602 — Ebastine Versus Mebeverine in IBS Patients · Phase 3 · recruiting

Other Christopher Almario trials

Trials by the same sponsor.

NCT07122843 — VR AI Meditation for Pain · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06687616 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Christopher Almario
Last refreshed: 8 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06687616.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing